Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Long-Term Debt Repayments (2024 - 2025)

OptimizeRx (OPRX) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed 0.0% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2025, up 100.0% year-over-year, with the annual reading at $8.0 million for FY2025, 100.0% up from the prior year.
  • Long-Term Debt Repayments hit $2.5 million in Q4 2025 for OptimizeRx, up from $500000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $4.5 million in Q2 2025 to a low of $500000.0 in Q1 2024.